Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation Positive Advanced Non-small-cell Lung Cancer”

118 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 118 results

Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Testing effectiveness (Phase 2)UnknownNCT05548348
What this trial is testing

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Who this might be right for
Non-small Cell Lung CancerEGFR G719XEGFR L861Q+1 more
Chongqing University Cancer Hospital 30
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Not applicableStudy completedNCT03790397
What this trial is testing

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

Who this might be right for
Non Small Cell Lung Cancer
Fundación GECP 169
Not applicableActive Not RecruitingNCT06376084
What this trial is testing

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract Neoplasms+7 more
AstraZeneca 532
Testing effectiveness (Phase 2)Study completedNCT03239340
What this trial is testing

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Who this might be right for
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 154
Early research (Phase 1)Looking for participantsNCT07315113
What this trial is testing

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc. 18
Not applicableUnknownNCT04391283
What this trial is testing

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Who this might be right for
Carcinoma, Non-Small-Cell Lung
First Affiliated Hospital of Zhejiang University 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410611
What this trial is testing

CtDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy

Who this might be right for
Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
Hebei Medical University Fourth Hospital 84
Early research (Phase 1)Study completedNCT02529995
What this trial is testing

Phase I, Study in Chinese NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
AstraZeneca 31
Testing effectiveness (Phase 2)Looking for participantsNCT06962865
What this trial is testing

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
RemeGen Co., Ltd. 80
Not applicableUnknownNCT03647592
What this trial is testing

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 30
Not applicableEnded earlyNCT02932345
What this trial is testing

Gefitinib Long-term Survivor Study

Who this might be right for
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
AstraZeneca 59
Not applicableStudy completedNCT03370770
What this trial is testing

Afatinib Osimertinib Sequencing NIS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 204
Not applicableStudy completedNCT04207775
What this trial is testing

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

Who this might be right for
Locally Advanced or Metastatic NSCLC
AstraZeneca 300
Testing effectiveness (Phase 2)UnknownNCT02725918
What this trial is testing

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 150
Large-scale testing (Phase 3)Active Not RecruitingNCT02438722
What this trial is testing

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
SWOG Cancer Research Network 174
Early research (Phase 1)Ended earlyNCT03711422
What this trial is testing

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Who this might be right for
Non-small Cell Lung CancerLeptomeningeal DiseaseCentral Nervous System Metastases
National Cancer Centre, Singapore 2
Testing effectiveness (Phase 2)UnknownNCT03460275
What this trial is testing

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 100
Load More Results